Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs 22nd Century Group Inc (XXII) Price & Performance

JPMorgan Ultra Short Income ETFTrade
22nd Century Group IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs 22nd Century Group Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.47, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.

JPSTXXII
Sector
Leveraged / InverseTechnology
52-Week High
$50.78$801.00
52-Week Low
$50.40$3.72
Market Cap
$1.52M
Enterprise Value
-$6.71M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% daily, with a bearish technical signal driven by moving averages. The fund focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends, including recent $0.17 payouts. Institutional holdings have increased, as seen in 13F filings from Financial Management Professionals Inc. and Ashton Thomas Securities LLC in Q2 2026, indicating steady investor interest amid a rising rate environment.

The outlook for JPST is stable, benefiting from its low-risk profile in volatile markets, but faces headwinds from potential Fed rate hikes that could pressure short-term bond yields. Risks include interest rate sensitivity and inflation concerns, yet it remains a core holding for conservative investors seeking yield with minimal volatility.

22nd Century Group Inc

XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.

The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.

Returns comparison

Trailing returns across standard periods

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About 22nd Century Group Inc

22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.

Read more on XXII